Ardelyx to Showcase Tenapanor Data at ASN Kidney Week 2026
Event summary
- Ardelyx will present three abstracts at ASN Kidney Week 2026, focusing on hyperphosphatemia management.
- Poster presentations will cover real-world effectiveness of tenapanor, patient perspectives, and morbidity/mortality risks.
- An Exhibitor Spotlight session will feature an in-depth look at XPHOZAH (tenapanor) on October 23, 2026.
- XPHOZAH is the only FDA-approved phosphate absorption inhibitor for CKD patients on dialysis.
The big picture
Ardelyx's presentation at ASN Kidney Week 2026 underscores the growing importance of innovative therapies in managing hyperphosphatemia, a critical condition for CKD patients on dialysis. The focus on real-world evidence and patient perspectives aligns with broader industry trends toward value-based healthcare and patient-centered outcomes. With XPHOZAH as its flagship product, Ardelyx is positioning itself as a key player in the nephrology space, competing against established phosphate binder therapies.
What we're watching
- Clinical Validation
- How the real-world effectiveness data will impact XPHOZAH's adoption among nephrologists.
- Market Differentiation
- Whether Ardelyx can position XPHOZAH as a superior alternative to traditional phosphate binders.
- Regulatory Dynamics
- The pace at which additional indications or label expansions for tenapanor could be pursued.
Related topics
